Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation
NCT02978274 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2020-10-05
Summary
Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution.
Conditions
- Natural Killer Cell Mediated Immunity
Interventions
- DRUG
-
MMF
MMF withdrawal by engraftment post haplo-SCT
- DRUG
-
MMF
MMF withdrawal by 2 month post haplo-SCT
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Principal Investigators
-
Xiaojun Huang, M.D., PhD · Peking University People's Hospital
Eligibility
- Min Age
- 15 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-03-31
- Primary Completion
- 2021-12-31
- Completion
- 2022-12-31
Countries
- China
Study Locations
More Related Trials
-
NK Cells Infusion for Advanced Malignancies
NCT03619954 ·Status: UNKNOWN ·Phase: PHASE1
-
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
NCT04298502 ·Status: UNKNOWN
-
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
NCT06509490 ·Status: RECRUITING ·Phase: NA
-
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341 ·Status: RECRUITING ·Phase: PHASE1
-
Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
NCT01801852 ·Status: UNKNOWN ·Phase: NA
-
NK Cell Therapy Recurrent/Refractory Elderly AML
NCT04599452 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Age-matched Reference Values for Circulating Natural Killer T-like Cells
NCT06450743 ·Status: COMPLETED ·Phase: NA
-
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders
NCT03123458 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
NCT05371730 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
NK Cells Treatment for COVID-19
NCT04280224 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
NCT00923390 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT04162158 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors
NCT07274449 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
NCT03047811 ·Status: UNKNOWN ·Phase: NA
-
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
NCT05131763 ·Status: UNKNOWN ·Phase: PHASE1
-
Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients
NCT02565589 ·Status: COMPLETED
-
The Role of NK Cells to Detect Blood Infection in ALL.
NCT06160115 ·Status: NOT_YET_RECRUITING
-
Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure
NCT07230574 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
NCT03882840 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
NCT00327236 ·Status: COMPLETED
-
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
NCT01394640 ·Status: COMPLETED
-
Vaccine Therapy in Treating Patients With Kidney Cancer
NCT00096629 ·Status: COMPLETED ·Phase: PHASE1
-
Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function
NCT00173290 ·Status: UNKNOWN
-
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906 ·Status: UNKNOWN ·Phase: PHASE1
-
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
NCT06568328 ·Status: RECRUITING ·Phase: PHASE1